ReviewNeurodegenerative disease management2014
Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs.
Review in Neurodegenerative disease management, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.
- Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer's disease models: a systematic review and meta-analysis of preclinical studies.Frontiers in pharmacology · 2023Pooled it
- Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.Nature medicine · 2026Trial
- "Morphological, Functional, and Molecular Progression of Blood-Brain Barrier Dysfunction in Alzheimer's Disease".Journal of molecular neuroscience : MN · 2026Review
- Hyperpolarized NMR study of the impact of alzheimer's disease on diabetes using a novel rat model.Journal of physiology and biochemistry · 2026Article
- GLP-1 receptor agonists, metabolic syndrome, and Alzheimer's disease: Lessons and opportunities from the EVOKE trials.Journal of neuroendocrinology · 2026Review
- Hippocampal Mitochondrial Dysfunction and Synaptic Disruption Link Organophosphate Exposure to Pre-Diabetes: An LC-MS/MS-Based Proteomics Approach.Biomolecules · 2026Article
- Acute amyloid-β exposure disrupts insulin signaling in hCMEC/D3 blood-brain barrier endothelial cells.Fluids and barriers of the CNS · 2026Article
- GLP-1 and the brain's powerhouse: a new perspective on the role of mitochondria in neuroprotection.Metabolic brain disease · 2026Review
- Acute amyloid-β exposure disrupts insulin signaling in blood-brain barrier endothelial cell culture models.Research square · 2026Article
- Zinc oxide nanoparticles mitigate insulin resistance in a D-galactose-induced C57BL/6 mouse model.Frontiers in endocrinology · 2026Article
- The Impact of Insulin Resistance on Grey Matter Changes Along the Alzheimer's Disease Continuum Insulin Resistance and Grey Matter in AD.medRxiv : the preprint server for health sciences · 2025Article
- Differences in inflammatory markers, mitochondrial function, and synaptic proteins in male and female Alzheimer's disease post mortem brains.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Mechanisms of cognitive impairment in arterial hypertension.World journal of psychiatry · 2025Article
- Analysis of ALPS-Index: Difference in Type 2 Diabetes Mellitus With or Without Mild Cognitive Impairment and Its Relationship With Hippocampal Microstructure.Brain and behavior · 2025Article
- Evaluating Genomic and Clinical Risk Factors for Alzheimer's Disease in Individuals with Hypertension.Biomedicines · 2025Article
- Tirzepatide: a novel therapeutic approach for Alzheimer's disease.Metabolic brain disease · 2025Review
- Chicken Primordial Germ Cells Do Not Proliferate in Insulin-Lacking Media.International journal of molecular sciences · 2025Article
- M3NetFlow: A multi-scale multi-hop graph AI model for integrative multi-omic data analysis.iScience · 2025Article
- Naringin and Naringenin: Potential Multi-Target Agents for Alzheimer's Disease.Current medical science · 2024Review
- M3NetFlow: A novel multi-scale multi-hop graph AI model for integrative multi-omic data analysis.bioRxiv : the preprint server for biology · 2024Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The prevalence of Alzheimer's disease is increasing rapidly in the absence of truly effective therapies. A promising strategy for developing such therapies is the treatment of brain insulin resistance, a common and early feature of Alzheimer's disease, closely tied to cognitive decline and capable of promoting many biological abnormalities in the disorder. The proximal cause of brain insulin resistance appears to be neuronal elevation in the serine phosphorylation of IRS-1, most likely due to amyloid-β-triggered microglial release of proinflammatory cytokines. Preclinically, the first line of defense is behavior-lowering peripheral insulin resistance (e.g., physical exercise and a Mediterranean diet supplemented with foods rich in flavonoids, curcumin and ω-3 fatty acids). More potent remediation is required, however, at clinical stages. Fortunately, the US FDA-approved antidiabetics exenatide (Byetta; Amylin Pharmaceuticals, Inc., CA, USA) and liraglutide (Victoza; Novo Nordisk A/S, Bagsvaerd, Denmark) are showing much promise in reducing Alzheimer's disease pathology and in restoring normal brain insulin responsiveness and cognitive function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.